Results 151 to 160 of about 12,292,416 (404)

Principles of nanoparticle design for overcoming biological barriers to drug delivery

Nature Biotechnology, 2015
Elvin Blanco, Haifa Shen, M. Ferrari
semanticscholar   +1 more source

Stemming the Global Trade in Falsified and Substandard Medicines [PDF]

, 2013
Drug safety and quality is an essential assumption of clinical medicine, but there is growing concern that this assumption is not always correct. Poor manufacturing and deliberate fraud occasionally compromises the drug supply in the United States, and ...
Buckley, Gillian J., Gostin, Lawrence O., Kelley, Patrick W.   +2 more
core   +2 more sources

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

On The Nature of Inhibition, And The Action of Drugs Upon it 1 [PDF]

, 1883
T. Lauder Brunton
openalex   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Measuring and Modeling of Melt Viscosity for Drug Polymer Mixtures

Pharmaceutics
Melt viscosity is an essential property in pharmaceutical processes such as mixing, extrusion, fused deposition modeling, and melt coating. Measuring and modeling of the melt viscosity for drug/polymer mixtures is essential for optimization of the ...
Vincent Kimmel, Enrico Ercolin, Robin Zimmer, Muhammet Yörük, Judith Winck, Markus Thommes   +5 more
doaj   +1 more source

Commercial Drug Growing in the United States in 1918**Read before Scientific Section, A. Ph. A., New York meeting, 1919. [PDF]

, 1919
W. W. Stockberger
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Problems of Antibiotics in Food as the Food and Drug Administration Sees Them

, 1957
Henry Welch
openalex   +2 more sources

SUCCESS IN DRUG COURT: THE OFFENDERS\u27 PERSPECTIVE [PDF]

, 2015
Drug Courts have demonstrated a reduction in recidivism in comparison to traditional probation programs. Prior studies have not addressed why drug courts are effective from the participants\u27 perspective.
Snell, Clete, Dr.
core   +1 more source